AIIMS, Jodhpur in India has received the Ethical Approval for "A clinical applicability study of the tumour specific electroporation technique for patients with locally advanced or recurrent head & neck cancer using IQwave 3.0 CE". 

The Investigator-Initiated Trial (IIT) was presented to the Ethical board by the Principal Investigator Dr. Jeewan Ram Vishnoi, Associate Professor, Department of Surgical Oncology, AIIMS, Jodhpur

The trial s conducted as part of the India-Sweden Healthcare Innovation Centre, a collaboration between AIIMS Delhi, AIIMS Jodhpur and Business Sweden - Swedish Trade Commissioner's Office.

The trial will start the enrolment of patients as soon as some changes to the protocol has been submitted.

"Tumour Specific Electroporation (TSE) is an evolving paradigm in the treatment of solid tumours with growing evidence not only for regional tumour control in a palliative care setting but also in earlier lines of curative treatment approaches. " - says Dr. Suhail Mufti Medical Adviser for ChemoTech

"We are very pleased that we are about to start one of the largest clinical projects in the history of ChemoTech. Even if we to date have treated hundreds of patients with different indications, we are still at the beginning of our journey. It is after reaching success in clinical trials with skilled and well-acknowledged organizations like AIIMS that our technology will come closer to becoming a contribution to standard therapy." - says Mohan Frick CEO 

This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 13-07-2022 08:55 CET.